MELBOURNE – OMNI Healthcare administered monoclonal antibody treatments (mAb) to more than 100 patients within two days last week. In response to updated recommendations from the National Institute of Health (NIH) Covid-19 Treatment Panel, OMNI will only be administering sotrovimab to patients with symptomatic Covid-19 and will no longer be providing bamlanivimab/etesevimab and casirivimab/imdevimab as treatment for non-hospitalized patients with symptomatic Covid-19.
While OMNI Healthcare will continue to administer sotrovimab, which is recommended by the NIH Covid-19 Treatment Panel, OMNI has exhausted its recent allocation of sotrovimab. OMNI Healthcare Director of Operations Andrew Waterman says OMNI expects to receive additional sotrovimab sometime soon. Due to the national shortage of sotrovimab, and new data regarding the severity of the Omicron variant, OMNI will be limiting eligibility to non-vaccinated patients who meet the CDC’s criteria.
OMNI will resume its monoclonal antibody (mAb) treatments at the following locations as soon as it receives additional sotrovimab.
1344 S. Apollo Blvd.
9 a.m. to 4 p.m.
845 Century Medical Dr.
1 p.m. to 4 p.m.
Anyone interested in receiving the treatments at OMNI will require evidence of a positive Covid-19 test result. Individuals must have symptoms and meet CDC criteria for administration of the monoclonal treatment. Interested individuals will be screened by phone to ensure they meet the criteria before appointments are scheduled.
Monoclonal treatments are helpful for people who are at risk for serious Covid-19 infection and have tested positive for the virus. The mAb treatment can block the SARS-CoV-2 virus (the virus that causes COVID-19) from entering the body’s cells and limit the amount of the virus within your body. This may result in milder symptoms and may decrease the likelihood of a hospital stay.
The mAb treatment may help people who: